Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology

Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology

Abstract Background Single patient Investigational New Drug (IND) applications are one mechanism through which experimental therapies are accessed for children with cancer. The landscape of use, outcomes, and toxicity from single patient INDs remains unknown in pediatric oncology. Methods We perform...

Full description

Bibliographic Details
Main Authors: David S. Shulman, Lulla V. Kiwinda, Stacey Edwards, Catherine M. Clinton, Sarah Hunt, Lianne Greenspan, Kristen D. Lawler, Gregory Reaman, Hasan Al‐Sayegh, Kira Bona, Allison F. O'Neill, Suzanne Shusterman, Katherine A. Janeway, Andrew E. Place, Susan N. Chi, Clement Ma, Steven G. DuBois
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
FDA
IND
investigational new drug
pediatric oncology
single patient IND
Online Access:https://doi.org/10.1002/cam4.3791

Internet

https://doi.org/10.1002/cam4.3791

Similar Items